English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Patient Groups: Spread the News
Patient Groups: Spread the News
Patient groups are uniquely placed to challenge fears and misperceptions that hamper prevention and contribute to late diagnoses, poor treatment and the social isolation of patients. Acting locally but using the Internet they are now campaigning globally. A recent article in "Cancerworld" also features the activities of The Max Foundation. See the article here.
Press Release: iCMLf launches ERSAP Program
New Foundation Launches Global Support and Partnership Program for Chronic Myeloid Leukemia (CML)
The newly formed International Chronic Myeloid Leukemia Foundation (iCMLf) has launched the Emerging Regions Support and Partnership (ERSAP) program at the annual meeting of the American Society of Hematology (ASH). The ERSAP Preceptorship Project will commence in 2010, providing training, education and support for 30 clinicians in emerging countries each year.
October is CML Awareness Month
October is CML Awareness Month
On October 1st, The Max Foundation opens a global awareness campaign to support survivors around the world by uniting people everywhere in the fight against cancer. The campaign aims at reducing the feelings of isolation of people facing cancer in developing countries and elsewhere.
Discussion Forum on Difficult CML Cases
New interactive forum for clinicians discussing difficult CML cases
To share and enhance best practice management of CML the iCMLf has opened a discussion forum where experts and interested clinicians can discuss difficult, or interesting CML patient cases. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) to the iCMLf web-site coordinator, Jan Geissler. Each case accepted will be published in the discussion forum with a brief response. Further comments, questions and discussion are invited.
